I found the below in the prospectus...which personally gives me confidence regarding the next couple of years and the likely outcome of these initial safety and efficacy tests.
"Early experiments in mice indicate RECCE 327 antibiotic particularly, is suited to treatment of parenteral infections and may be administered by a range of methods; the treatment may be prophylactic (preventative) or curative. In experiments within an independent laboratory in USA, a single dose of RECCE 327 was injected into mice, and effectively killed the superbug Methicillin Resistant S. aureus (MRSA)."
Bring on Phase 1...as I don't see it likely that we have problems in these initial animal trials. Fingers crossed!
RCE Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)